BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response
September 28, 2021 11:17 ET | BioAegis Therapeutics
This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype. NORTH BRUNSWICK, New Jersey, Sept. 28, 2021 (GLOBE NEWSWIRE) --...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET | BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Equillium_Square_Logo.png
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
October 29, 2020 16:13 ET | Equillium
Equillium plans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020 FDA indicates study could support BLA filing LA JOLLA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Equillium,...
Equillium_Square_Logo.png
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
September 15, 2020 08:07 ET | Equillium
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc....
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity
August 17, 2020 10:57 ET | BioAegis Therapeutics
BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic MORRISTOWN, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
August 05, 2020 18:16 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
July 15, 2020 13:34 ET | BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...
Equillium_Square_Logo.png
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
July 13, 2020 03:30 ET | Equillium
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
June 23, 2020 17:21 ET | BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...